Comparative effectiveness and safety of nab-paclitaxel plus carboplatin vs gemcitabine plus carboplatin in first-line treatment of advanced squamous cell non-small cell lung cancer in a US community oncology setting

Raja Mudad,1 Manish B Patel,2 Sandra Margunato-Debay,2 David Garofalo,3 Lincy S Lal4 1University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center, Hollywood, FL, USA; 2Celgene Corporation, Summit, NJ, USA; 3Cardinal Health, Dallas, TX, USA; 4University of Texas School of Pub...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mudad R, Patel MB, Margunato-Debay S, Garofalo D, Lal LS
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	Chemotherapy doublet treatment options electronic medical records NSCLC real-world evidence retrospective analysis Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/a44e6c494f2141c8b3de11c079cf5d2f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a44e6c494f2141c8b3de11c079cf5d2f
record_format	dspace
spelling	oai:doaj.org-article:a44e6c494f2141c8b3de11c079cf5d2f2021-12-02T00:10:38ZComparative effectiveness and safety of nab-paclitaxel plus carboplatin vs gemcitabine plus carboplatin in first-line treatment of advanced squamous cell non-small cell lung cancer in a US community oncology setting1179-2728https://doaj.org/article/a44e6c494f2141c8b3de11c079cf5d2f2017-10-01T00:00:00Zhttps://www.dovepress.com/comparative-effectiveness-and-safety-of-nab-paclitaxel-plus-carboplati-peer-reviewed-article-LCTThttps://doaj.org/toc/1179-2728Raja Mudad,1 Manish B Patel,2 Sandra Margunato-Debay,2 David Garofalo,3 Lincy S Lal4 1University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center, Hollywood, FL, USA; 2Celgene Corporation, Summit, NJ, USA; 3Cardinal Health, Dallas, TX, USA; 4University of Texas School of Public Health, Houston, TX, USA Introduction: Real-world comparative effectiveness, safety, and supportive care use of nab-paclitaxel plus carboplatin vs gemcitabine plus platinum were analyzed in patients with advanced or metastatic squamous cell non-small cell lung cancer (NSCLC).Materials and methods: Patients who received ≥ 1 cycle of first-line nab-paclitaxel plus carboplatin or gemcitabine plus platinum were identified from the Navigating Cancer database. Clinical effectiveness endpoints included overall survival (OS) and time to treatment discontinuation (TTD). Other endpoints included safety and utilization of supportive care. Cox proportional hazards models were used to control for potential confounding effects of baseline characteristics.Results: In total, 193 patients were included (nab-paclitaxel plus carboplatin, n = 61; gemcitabine plus platinum, n = 132). Baseline characteristics were generally similar between the cohorts. Patients receiving nab-paclitaxel plus carboplatin had a significantly longer OS than those receiving gemcitabine plus carboplatin (median, 12.8 vs 9.0 months; P = 0.03). However, the adjusted difference was not statistically significant (adjusted HR 1.55; 95% CI, 0.99–2.42; P = 0.06). nab-Paclitaxel plus carboplatin-treated patients had significantly longer TTD than gemcitabine plus carboplatin-treated patients (median, 4.3 vs 3.5 months; P = 0.03; adjusted HR 1.39; 95% CI, 1.01–1.90; P = 0.04). Grade 3 or 4 anemia and neutropenia were significantly lower in patients treated with nab-paclitaxel plus carboplatin vs gemcitabine plus carboplatin. Nausea and neuropathy (grade not specified) were significantly higher in the nab-paclitaxel plus carboplatin than the gemcitabine plus carboplatin group. No differences in supportive care use were observed between the cohorts.Conclusion: These real-world data support the effectiveness and safety of nab-paclitaxel plus carboplatin for first-line treatment of advanced squamous cell NSCLC. Keywords: chemotherapy, doublet treatment options, electronic medical records, NSCLC, real-world evidence, retrospective analysisMudad RPatel MBMargunato-Debay SGarofalo DLal LSDove Medical PressarticleChemotherapydoublet treatment optionselectronic medical recordsNSCLCreal-world evidenceretrospective analysisNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENLung Cancer: Targets and Therapy, Vol Volume 8, Pp 179-190 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Chemotherapy doublet treatment options electronic medical records NSCLC real-world evidence retrospective analysis Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Chemotherapy doublet treatment options electronic medical records NSCLC real-world evidence retrospective analysis Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Mudad R Patel MB Margunato-Debay S Garofalo D Lal LS Comparative effectiveness and safety of nab-paclitaxel plus carboplatin vs gemcitabine plus carboplatin in first-line treatment of advanced squamous cell non-small cell lung cancer in a US community oncology setting
description	Raja Mudad,1 Manish B Patel,2 Sandra Margunato-Debay,2 David Garofalo,3 Lincy S Lal4 1University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center, Hollywood, FL, USA; 2Celgene Corporation, Summit, NJ, USA; 3Cardinal Health, Dallas, TX, USA; 4University of Texas School of Public Health, Houston, TX, USA Introduction: Real-world comparative effectiveness, safety, and supportive care use of nab-paclitaxel plus carboplatin vs gemcitabine plus platinum were analyzed in patients with advanced or metastatic squamous cell non-small cell lung cancer (NSCLC).Materials and methods: Patients who received ≥ 1 cycle of first-line nab-paclitaxel plus carboplatin or gemcitabine plus platinum were identified from the Navigating Cancer database. Clinical effectiveness endpoints included overall survival (OS) and time to treatment discontinuation (TTD). Other endpoints included safety and utilization of supportive care. Cox proportional hazards models were used to control for potential confounding effects of baseline characteristics.Results: In total, 193 patients were included (nab-paclitaxel plus carboplatin, n = 61; gemcitabine plus platinum, n = 132). Baseline characteristics were generally similar between the cohorts. Patients receiving nab-paclitaxel plus carboplatin had a significantly longer OS than those receiving gemcitabine plus carboplatin (median, 12.8 vs 9.0 months; P = 0.03). However, the adjusted difference was not statistically significant (adjusted HR 1.55; 95% CI, 0.99–2.42; P = 0.06). nab-Paclitaxel plus carboplatin-treated patients had significantly longer TTD than gemcitabine plus carboplatin-treated patients (median, 4.3 vs 3.5 months; P = 0.03; adjusted HR 1.39; 95% CI, 1.01–1.90; P = 0.04). Grade 3 or 4 anemia and neutropenia were significantly lower in patients treated with nab-paclitaxel plus carboplatin vs gemcitabine plus carboplatin. Nausea and neuropathy (grade not specified) were significantly higher in the nab-paclitaxel plus carboplatin than the gemcitabine plus carboplatin group. No differences in supportive care use were observed between the cohorts.Conclusion: These real-world data support the effectiveness and safety of nab-paclitaxel plus carboplatin for first-line treatment of advanced squamous cell NSCLC. Keywords: chemotherapy, doublet treatment options, electronic medical records, NSCLC, real-world evidence, retrospective analysis
format	article
author	Mudad R Patel MB Margunato-Debay S Garofalo D Lal LS
author_facet	Mudad R Patel MB Margunato-Debay S Garofalo D Lal LS
author_sort	Mudad R
title	Comparative effectiveness and safety of nab-paclitaxel plus carboplatin vs gemcitabine plus carboplatin in first-line treatment of advanced squamous cell non-small cell lung cancer in a US community oncology setting
title_short	Comparative effectiveness and safety of nab-paclitaxel plus carboplatin vs gemcitabine plus carboplatin in first-line treatment of advanced squamous cell non-small cell lung cancer in a US community oncology setting
title_full	Comparative effectiveness and safety of nab-paclitaxel plus carboplatin vs gemcitabine plus carboplatin in first-line treatment of advanced squamous cell non-small cell lung cancer in a US community oncology setting
title_fullStr	Comparative effectiveness and safety of nab-paclitaxel plus carboplatin vs gemcitabine plus carboplatin in first-line treatment of advanced squamous cell non-small cell lung cancer in a US community oncology setting
title_full_unstemmed	Comparative effectiveness and safety of nab-paclitaxel plus carboplatin vs gemcitabine plus carboplatin in first-line treatment of advanced squamous cell non-small cell lung cancer in a US community oncology setting
title_sort	comparative effectiveness and safety of nab-paclitaxel plus carboplatin vs gemcitabine plus carboplatin in first-line treatment of advanced squamous cell non-small cell lung cancer in a us community oncology setting
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/a44e6c494f2141c8b3de11c079cf5d2f
work_keys_str_mv	AT mudadr comparativeeffectivenessandsafetyofnabpaclitaxelpluscarboplatinvsgemcitabinepluscarboplatininfirstlinetreatmentofadvancedsquamouscellnonsmallcelllungcancerinauscommunityoncologysetting AT patelmb comparativeeffectivenessandsafetyofnabpaclitaxelpluscarboplatinvsgemcitabinepluscarboplatininfirstlinetreatmentofadvancedsquamouscellnonsmallcelllungcancerinauscommunityoncologysetting AT margunatodebays comparativeeffectivenessandsafetyofnabpaclitaxelpluscarboplatinvsgemcitabinepluscarboplatininfirstlinetreatmentofadvancedsquamouscellnonsmallcelllungcancerinauscommunityoncologysetting AT garofalod comparativeeffectivenessandsafetyofnabpaclitaxelpluscarboplatinvsgemcitabinepluscarboplatininfirstlinetreatmentofadvancedsquamouscellnonsmallcelllungcancerinauscommunityoncologysetting AT lalls comparativeeffectivenessandsafetyofnabpaclitaxelpluscarboplatinvsgemcitabinepluscarboplatininfirstlinetreatmentofadvancedsquamouscellnonsmallcelllungcancerinauscommunityoncologysetting
_version_	1718403880521302016

Comparative effectiveness and safety of nab-paclitaxel plus carboplatin vs gemcitabine plus carboplatin in first-line treatment of advanced squamous cell non-small cell lung cancer in a US community oncology setting

Ejemplares similares